Treeline Biosciences, a stealth oncology biotech founded by veterans Josh Bilenker and Jeff Engelman, publicly disclosed its first clinical programs and a $200 million series A extension, bringing total funding to approximately $1.1 billion. The company’s pipeline includes protein degraders targeting lymphoma and solid tumor KRAS mutations, plus an EZH2 inhibitor licensed from Jiangsu Hengrui Pharmaceuticals. Treeline’s approach spans multiple therapeutic modalities and aims to disaggregate the typical milestone-driven biotech model by resourcing several programs with varied risk profiles and time horizons. The company’s substantial capital infusion and clinical advancement signal a major presence in cancer drug development innovation.